Skip to main content
Premium Trial:

Request an Annual Quote

RXi Q2 Losses Up on Spinout-Related Expenses


RXi Pharmaceuticals this week released its second-quarter financial results, posting a surge in losses tied to its spinout from former parent firm Galena Biopharma (GSN 5/10/2012).

For the three-month period ended June 30, RXi's net loss jumped to $17.2 million, or $0.13 a share, from a year-ago loss of $1.9 million, or $0.05 a share. According to the company, the increase was largely the result of a $9.6 million non-cash dividend “relating to the beneficial conversion feature as a result of the issuance of convertible preferred stock” in late April when Galena sold 83 percent of RXi to institutional shareholders.

RXi's research and development spending soared to $6.9 million from $1.8 million during the same period last year, a rise in part related to costs associated with the acquisition of patent and technology rights during the spin-off process.

General and administrative costs, meantime, fell to $700,000 from $1 million.

At the end of the second quarter, RXi had cash and cash equivalents totaling $7.6 million, which it said should be sufficient to fund operations into the second quarter of next year.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.